Clinical Trials
64 trialsComparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among Patients With Stage IV Non-small Cell Lung Cancer Receiving Pembrolizumab
City of Hope Medical Center
ALCG-01
Gazi University
GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer
Roswell Park Cancer Institute
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
M.D. Anderson Cancer Center
ATATcH Alternating Treatment Plans for Advanced Cancer
Rutgers, The State University of New Jersey
PEERS
Fundación GECP
Perioperative Immunotherapy for NSCLC (ECTOP-1030)
Fudan University
POTENT
Institute of Cancer Research, United Kingdom
PANDA-VAC
UNC Lineberger Comprehensive Cancer Center
Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-Lung Study
M.D. Anderson Cancer Center
Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors
Mayo Clinic
PNeoVCA
Mayo Clinic
Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC (DFMO)
H. Lee Moffitt Cancer Center and Research Institute
MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)
Providence Health & Services
EBNK-ST-001
Essen Biotech
Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer
Emory University
Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy
Emory University
DoceRamPem
Emory University
Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced
M.D. Anderson Cancer Center
Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC)
H. Lee Moffitt Cancer Center and Research Institute
LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer
University of Washington
CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer
Roswell Park Cancer Institute
Pembro+Chemo in Brain Mets
University of Kentucky
Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin
Memorial Sloan Kettering Cancer Center
A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors
Memorial Sloan Kettering Cancer Center
A Study of Orally Administered JBI-802 Alone or in Combination With Pembrolizumab for Patients With Non-small Cell Lung Cancer With an STK11 Mutation.
The Christ Hospital
TROPICAL-1
Latin American Cooperative Oncology Group
Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.
Memorial Sloan Kettering Cancer Center
Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Cancer
Ohio State University Comprehensive Cancer Center
SWIPE
Bank of Cyprus Oncology Centre
Immunotherapy With or Without SBRT in Patients With Stage IV Non-small Cell Lung Cancer
Wake Forest University Health Sciences
Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
Pembrolizumab After Radiation Therapy and Chemotherapy in Limited Stage Small Cell Lung Cancer
Vanderbilt-Ingram Cancer Center
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer
Thomas Jefferson University
Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung Cancer
Chinese University of Hong Kong
Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC
Yale University
Replay
Spanish Lung Cancer Group
CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer
Jonsson Comprehensive Cancer Center
Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer
Vanderbilt-Ingram Cancer Center
BAH2472
Essen Biotech
Microbiota Transplant in Advanced Lung Cancer Treated With Immunotherapy
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Intra-tumor Injection of Drug-eluting Microspheres With Multiple Drugs
Second Affiliated Hospital of Guangzhou Medical University
BECOME
Hunan Province Tumor Hospital
Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.
Second Affiliated Hospital of Guangzhou Medical University
Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University
Pembrolizumab Alone or Sequentially Following Single Fraction Non-ablative Radiation to One of the Target Lesions, in Previously Treated Patients With Stage IV NSCLC
Case Comprehensive Cancer Center
Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies
University of California, San Francisco